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Abstract
Background: Activated hepatic stellate cell (HSC) is the main fibrogenic cell type in the injured liver. miRNA plays
an important role in activation and proliferation of HSC.
Methods: Our previous study examined the expression profiles of microRNAs in quiescent and activated HSC.
Real-time PCR and western blot were used to detect the expression of Collagen type I (Col 1) and Alpha-Smooth
Muscle Actin (α-SMA). CCK-8 and Edu assay was used to measure the proliferation rate of HSC. Luciferase reporter
gene assay was used to tested the binding between miR-338-3p and Cyclin-dependent kinase 4 (CDK4).
Results: We found overexpression of miR-338-3p could inhibit Col 1 and α-SMA, two major HSC activation
markers, whereas miR-338-3p inhibitor could promote them. Besides, miR-338-3p overexpression could suppress
the growth rate of HSC. Further, we found that CDK4, a pleiotropic signaling protein, was a direct target gene of
miR-338-3p. Moreover, we found that overexpression of CDK4 could block the effects of miR-338-3p.
Conclusions: We found miR-338-3p is an anti-fibrotic miRNA which inhibits cell activation and proliferation. Our
findings suggest that miR-338-3p/CDK4 signaling pathway participates in the regulation of HSC activation and
growth and may act as a novel target for further anti-fibrotic therapy.
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Background
Liver fibrosis is a common consequence of most chronic
liver diseases [1]. Liver fibrosis received more attention
until the hepatic stellate cell (HSC) was identified as the
main ECM-producing cells in the injured liver [2].
Under the normal physiologic condition, HSCs reside in
the space of disse and store a large amount of vitamin A.
After suffering from liver injury, HSCs will be activated,
and then proliferate, eventually transdifferentiate into
myofibroblast-like cells [3].
microRNAs (miRNAs), short (~22 nt) conceding RNA
molecules, can directly regulate gene expression by binding
to the 3’UTR region of target mRNA to participate in lots
of regulation of physiological process and diseases [4–8].
Recently, researchers focused on the role of miRNA in liver
fibrosis pathophysiology to determine their regulatory ef-
fects on proliferation, differentiation of HSC [9–11]. Several
abnormally expressed miRNAs were found and identified
between quiescent and activated HSCs by using miRNA
array or RT-PCR [12–19]. Previous studies have reported
that miRNAs were critically involved in the activation of
HSCs. Among them, miR-29b precursor allowed activated
HSCs to switch to a more quiescent state [10]. Similarly,
overexpression of miR-27a/b could lead HSCs to a quies-
cent phenotype [20]. microRNA-338 (miR-338), a newly
identified miRNA, played a crucial role in a variety of
carcinomas. Aberrant expression of miR-338 was closely
related to cell proliferation, invasion, early detection and
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clinic pathologic variables in liver cancer, colorectal cancer,
gastric cancer and neuroblastoma [21–25]. In previous
research, our miRNA microarray data have found altered
expression of miR-338-3p during culture activation of HSC
[14]. However, little is known about the role of miR-338-3p
in liver fibrosis.
Cyclin-dependent kinase 4 (CDK4) is found to be in-
volved in cell cycle regulation. Activation of cyclin
D—CDK4 promotes the cell cycle progression through
G1/S transition [26]. Inhibition of CDK4 shows promising
efficacy on advanced breast cancer [27]. In liver tissue and
hepatoma cells, CDK4/6 inhibition is a potent mediator of
cytostasis [28]. However, whether the CDK4 participates
in the fibrogenic process and regulates HSC activation
and proliferation remains largely unknown. In this study,
RT-PCR data suggested that miR-338-3p expression in
fully activated HSCs were significantly decreased com-
pared with that in quiescent HSCs. Transforming growth
factor (TGF-β) is deemed to be the most potent fibrogenic
cytokine. The results showed that there was a negative
relationship between TGF-β and miR-338-3p. Therefore,
we speculated that miR-338-3p was closely associated with
HSCs function. Then, we found overexpression of miR-
338-3p could suppress HSCs activation and proliferation
while inhibition of miR-338-3p could promote HSCs
activation and proliferation. Based on the Bioinformatics
prediction, we found that CDK4 was a potential target
gene of miR-338-3p. Further luciferase reporter assay and
RT-PCR confirmed their complementary binding. More-
over, our results indicated that overexpression of CDK4
could partially block miR-338-3p-inhibited cell activation
and proliferation.
Methods
Primary rat HSCs, cell lines and culture
The isolation method of primary rat HSCs was accord-
ing to the previous literature [29]. Primary Rat HSCs,
HSC-T6 and HEK293T (human embryonic kidney cell
line) were kindly gifted from Dr. Gao (Tongji University,
Shanghai, China). The primary cells and cell lines were
cultured in DMEM (Dulbecco’s modified Eagle’s
medium, Thermo, Waltham, MA, USA) containing 10%
FBS (Fetal bovine serum, FBS, Gibco, Grand Island, NY,
USA) at 37 °C in a humidified atmosphere of 5% CO2.
Plasmid construction
Wild-type 3’UTR containing predicted miR-338-3p
binding sites were amplified from HSC-T6 genomic
DNA and inserted into the PGL3 luciferase reporter
vector. Mutant 3’UTR was generated using the Quick
Change Lighting Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA, USA). The CDK4
expression vector was obtained by cloning the CDK4-
coding sequence into the pcDNA.
RT-PCR analysis
Total RNA was extracted from cultured HSCs using
Trizol Reagent (Takara, Dalian, China). The primer
sequences used for mRNA detection in this study were
listed as follows: GAPDH (PF: CAGTGCCAGCCTCG
TCTCAT, PR: AGGGGCCATCCACAGTCTTC); ColI
(PF: ATCCTGCCGATGTCGCTAT, PR: CCACAAGCG
TGCTGTAGGT); α-SMA (PF: CCGAGATCTCACCG
ACTACC, PR: TCCAGAGCGACATAGCACAG); CDK4
(PF: GAAGAAGAAGCGGAGGAAGAGG, PR: TTAGGT
TAGTGCGGGAATGAAT).
CCK-8 assay and Edu assay
Cell proliferation was performed using CCK-8 assay
(Dojindo, Japan) and Edu (Ribibio, Guangzhou, China)
assay. For CCK-8, HSC-T6 was transfected with the miR-
338 precursor, miR-338 inhibitor (Ribibio, Guangzhou,
China) or pcDNA-CDK4 in 96 well culture plates. Prolifera-
tion rates were tested at 24, 48 and 72 h after transfection.
The EdU assay was conducted according to the protocol of
Ribibio Edu Kit.
Luciferase assay
Luciferase assay was performed with the Dual Luciferase
Reporter Assay System (Promega, Madison, WI). Trans-
fection was carried out in 48 well plates using Fugen
(Roche). There were two groups. One was co-transfected
with 200 ng wild-type-CDK4-3’UTR, 20 nm miR-338 pre-
cursor, and 20 ng Renilla. Another was co-transfected with
200mutant CDK4 3’UTR without binding site of miR-338-
3p, 20 nm miR-338 precursor, and 20 ng Renilla. 48 h later,
Firefly and Renilla luciferase activities were tested.
Western blotting
Cells were lysed in SDS sample buffer. Antibodies
against GAPDH (Biogot, 1:5000 dilution, Nanjing,
China), Col1 (Abcam, 1:1500 dilution, Cambridge, MA,
USA), α-sma (Sigma, 1:1000 dilution, Shanghai, China)
and CDK4 (Biogot, 1:3000 dilution, Nanjing, China)
were used in this study. Signals were visualized with
ImageQuant LAS 4000 (GE Healthcare Life Sciences).
Statistical analysis
The statistical analysis in our study was performed by
using SPSS 22.0. Data were given as mean ± SEM. Two
tailed t-test was used to determine between two groups.
Statistical significance level was set at p < 0.05.
Results
miR-338-3p was downregulated in fully activated HSCs
Based on the microarray data, multitude ectopic miR-
NAs were detected in the HSCs. In our previous study,
we isolated rat primary HSCs and extracted total RNA
to perform miRNA microarray assay. Our attention was
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focused on miR-338-3p, a new underlying member of liver
fibrosis. The microarray data showed that the expression of
miR-338-3p was sharply reduced by 90% at day 7 (partially
activated HSCs) [14]. To validate this finding, RT-PCR was
carried out to measure the endogenous miR-338-3p expres-
sion in a quiescent state and an activated state. As primary
HSCs were gradually activated during culture, we assessed
miR-338-3p expression at day 2, day 7 and day 14 after
isolation. Our data indicated that endogenous miR-338-3p
expression was obviously reduced at day 7 and day 14
(Fig. 1a). Meanwhile, collagen type I (Col1) and α-sma (α-
smooth muscle actin, α-SMA), two key biomarkers of HSCs
activation, was gradually increased (Fig. 1b, c). In addition,
we found that treatment with transforming growth factor
(TGF-β, 2 ng/ml) in quiescent HSCs (day 2), the expression
of miR-338-3p was reduced rapidly (Fig. 1d). When cells
were fully activated (day 14), we treated them with
SB431542, a potent and specific inhibitor of TGF-β and
detected the level of miR-338-3p. The results suggested that
the expression of miR-338-3p was increased compared to
that in control group (Fig. 1e).
Overexpression of miR-338-3p suppressed HSC activation
while inhibition of it promoted HSC activation
As we discovered, miR-338-3p was significantly de-
creased during the process of activation, we transfected
miR-338 precursor to repair its loss at the early stage of
primary HSCs. On day 7, cells transfected with miR-338
precursor showed a more original shape with less per-
ipheral protrusions. However, the control group cells
showed a more irregular shape with more peripheral
protrusions (Fig. 2a). As results showed in Figs. 1b, c
and 2a, it seemed that there was a negative relationship
between miR-338 expression and HSCs activation. We
assumed that the expression of miR-338-3p was involved
in this activation process. To confirm our hypothesis, we
alter the miR-338-3p expression in primary HSC by
transfecting miR-338 precursor. Interestingly, the
expression of Col 1 and α-sma was slightly decreased
due to the upregulation of miR-338-3p (Fig. 2b). Due to
the low efficiency of transfection in primary cells, HSC-
T6 cell line was further used to conduct the following
studies. To replicate the results, HSC-T6 cell line was
transfected with miR-338 precursor or negative control.
48 h later, cells were collected and transfection efficiency
was confirmed by RT-PCR (Fig. 2c). Then the expression
of Col1 and α-sma in two groups was measured using
RT-PCR. As expected, the data showed miR-338-3p
inhibited HSCs activation. The expression of Col1 and
α-sma was respectively reduced as a result of miR-338-
3p overexpression (Fig. 2d, e). Furthermore, inhibition of
miR-338-3p could upregulate Col1 and α-sma which
Fig. 1 Expression of miR-338-3p is reduced in HSCs during culture activation. a miR-338-3p expression in the HSCs during culture activation. Data
shown are means ± SD (n = 3), ***P < 0.001. b mRNA level of Col1 in the HSCs during cell culture. Data shown are means ± SD (n = 3), **P < 0.01. c
mRNA level of α-sma in the HSCs during cell culture. Data shown are means ± SD (n = 3), **P < 0.01, ***P < 0.001. d miR-338-3p expression of
quiescent HSCs was reduced upon TGF-β treatment. Data shown are means ± SD (n = 3), *P < 0.05. e miR-338-3p expression of activated HSCs
was increased upon SB431542 treatment. Data shown are means ± SD (n = 3), *P < 0.05
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confirm their association on the other direction (Fig. 2f, g).
Their expression was also confirmed at the protein level
(Fig. 2h).
Overexpression of miR-338 suppressed HSC-T6
proliferation
Next, we examined the impacts of miR-338 on HSCs
proliferation. HSC-T6 were transfected with miR-338
precursor, inhibitor or corresponding negative control.
In the CCK-8 assay, the cell growth curves suggested
that overexpression of miR-338 significantly restrained
HSC-T6 proliferation in a time-dependent manner
(Fig. 3a.). Moreover, cells transfected with miR-338
inhibitor showed a higher proliferative ability (Fig. 3b).
Edu incorporation assay also demonstrated that miR-338
precursor reduced the proliferation of HSC-T6 (Fig. 3c-d).
Besides proliferation, we also assessed the role of miR-338-
3p in HSCs migration. As Fig. 3e, f showed, miR-338-3p
has no effects on cell migration.
miR-338 repressed CDK4 expression by directly binding
to its 3’UTR region
Based on the prediction of Bioinformatics (TargetScan,
PicTar), some genes are predicted to be the targets of
miR-338-3p. Among them, we hypothesized CDK4, an
oncogene in liver cancer, might be a putative target gene
Fig. 2 Overexpression of miR-338-3p could inhibit cell activation, whereas inhibition of miR-338 could promote cell activation. a The cell
morphology of HSCs after transfecting with miR-338 precursor or negative control. b The expression of miR-338, Col1, and α-SMA in
primary HSCs was tested after miR-338-precursor transfection. c miR-338-3p transfection efficiency was confirmed by qRT-PCR. Data shown
are means ± SD (n = 3), **P < 0.01. d mRNA level of Col1 in the HSCs transfected with miR-338 precursor or negative control. Data shown
are means ± SD (n = 3), *P < 0.05. e mRNA level of α-sma in the HSCs transfected with miR-338 precursor or negative control. Data shown
are means ± SD (n = 3), **P < 0.01. f mRNA level of Col1 in the HSCs transfected with miR-338-3p inhibitor or negative control. Data shown
are means ± SD (n = 3), *P < 0.05. g mRNA level of α-sma in the HSCs transfected with miR-338-3p inhibitor or negative control. Data
shown are means ± SD (n = 3), *P < 0.05. h Protein level of Col1 and sma by western blot
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Fig. 3 (See legend on next page.)
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Fig. 3 miR-338-3p regulates cell proliferation and CDK4. a The proliferation analysis of HSC-T6 transfected with miR-338 precursor or negative control.
Data shown are means ± SD (n= 3). **P < 0.01 versus the corresponding control. b The proliferation analysis of HSC-T6 transfected with miR-338 inhibitor
or negative control. Data shown are means ± SD (n= 3). **P< 0.01 versus the corresponding control. c Micrograph of HSC-T6 transfected with miR-338
precursor. d Edu incorporation assay demonstrated that miR-338 precursor reduced the proliferation of HSC-T6. Data shown are means ± SD (n= 3). ***P
< 0.001. e, f HSCs migration was measured by transwell assay. g The predicted sequence of binding region between miR-338-3p and CDK4. h Luciferase
activity of CDK4 3’UTR WT reporter vector co-transfected with miR-338-3p. Data shown are means ± SD (n = 3). **P< 0.01. i Luciferase activity of CDK4
3’UTR mutant reporter vector co-transfected with miR-338-3p. Data shown are means ± SD (n= 3). j mRNA level of CDK4 in the HSCs transfected with
Pre-miR-338-3p or negative control. Data shown are means ± SD (n= 3). **P< 0.01. k mRNA level of CDK4 in the HSCs transfected with miR-338-inhibitor
or negative control. Data shown are means ± SD (n= 3). **P< 0.01. l The expression of CDK4 was restrained by miR-338-precursor, whereas recovered by
miR-338 inhibitor
Fig. 4 Overexpression of CDK4 could partially rescue the effects of miR-338-3p upon HSCs. a The proliferation analysis of HSC-T6 cells transfected with
CDK4 vector or empty control. Data shown are means ± SD (n= 3). *P< 0.05, **P< 0.01 versus the corresponding control. b mRNA level of Col1 in the
HSCs transfected with CDK4 vector or empty control. Data shown are means ± SD (n= 3), *P < 0.05. c mRNA level of α-sma in the HSCs transfected with
CDK4 vector or empty control. Data shown are means ± SD (n = 3), **P < 0.01. d The proliferation analysis of HSC-T6 cells co-transfected
with miR-338 precursor and CDK4 plasmid. Data shown are means ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. e mRNA level of Col1 in
the HSC-T6 cells co-transfected with miR-338 precursor and CDK4 plasmid. Data shown are means ± SD (n = 3), *P < 0.05. f mRNA level of
α-sma in the HSC-T6 cells co-transfected with miR-338 precursor and CDK4 plasmid. Data shown are means ± SD (n = 3), **P < 0.01. g
Protein level of Col1, α-sma in the HSC-T6 cells co-transfected with miR-338 precursor and CDK4 plasmid
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of miR-338-3p in liver fibrosis. The predicted sequence
of interaction was showed in Fig. 3g. To test this predic-
tion, 3’UTR with miR-338-3p binding sites were cloned
into the PGL3 luciferase reporter vector. A mutant
3’UTR of CDK4 with anti-sense mutation in the pre-
dicted sites was also constructed. The reporter construct
was co-transfected into HEK293T with Renilla plasmid
and miR-338 precursor or negative control. The wild-
type CDK43’UTR luciferase activity was suppressed due
to miR-338-3p overexpression. By contrast, the activity
of mutant-3’UTR-CDK4 remained relatively unaffected
(Fig. 3h, i). Additionally, CDK4 expression was decreased
in the miR-338 precursor group while increased in the
miR-338 inhibitor group (Fig. 3j, k). miR-338-3p could
also regulate CDK4 at protein level (Fig. 4l). Taken
together, these data strongly suggested that miR-338-3p
repressed CDK4 expression by directly binding to its
3’UTR region.
CDK4 rescued miR-338-inhibition of activation and prolif-
eration of HSCs
Since miR-338 regulated cell growth, cell migration and
cell invasion in liver cancer and colorectal carcinoma by
targeting CDK4 [21, 30], the role of CDK4 in liver fibro-
sis remained unclear.
We conduct CCK-8 assay to determine the proliferation
of HSC-T6 transfected with CDK4 plasmid or control
empty vector. The results showed that cell transfected with
CDK4 plasmid displayed a higher proliferative capacity
compared with the control group (Fig. 4a). Besides, we
found cells transfected with CDK4 could promote cell
activation with upregulation of Col1 and α-Sma (Fig. 4b, c).
We co-transfected HSC-T6 cells with miR-338 precursor
and CDK4 plasmid to investigate whether CDK4
would rescue the inhibition effect of miR-338 on the
cell activation and proliferation or not. The results
suggested that overexpression of CDK4 partially block
the repression effect of miR-338 on the activation and
proliferation of HSC-T6. The growth curves of three
groups (Control, Pre-miR-338/pcDNA, Pre-miR-338/
CDK4) were shown in Fig. 4d. The expression of activa-
tion associated markers, Col1 andα-Sma, was showed in
Fig. 4e-f.
Discussion
Liver fibrosis is a scarring response to liver damage. It’s a
common pathological process for most of the liver disorder.
A small number of patients go on to progress cirrhosis
and/or hepatocellular carcinoma. Fortunately, liver fibrosis
can be reversed if the inflammation was controlled [31].
Aberrant expression of miRNAs have been involved in
liver fibrosis and regarded as a potential treatment strat-
egy. Intervening miRNAs expression could assist acti-
vated HSCs to return to a quiescent phenotype. miRNA
microarray and RT-PCR was carried out to determine
abnormally expressed miRNAs during HSCs activation.
Our results suggested that miR-338-3p was significantly
downregulated in this process. miR-338 is located on
chromosome 17q25.3 with a length of 22 nt and
produces two mature forms, miR-338-3p and miR-338-
5p. miR-338 was first reported in neurodegeneration and
gradually studied in various disease [32]. In hepatocellu-
lar carcinoma, miR-338 downregulation was associated
with tumor size, TNM stage, vascular invasion and in
trahepatic metastasis [21, 22]. In colorectal carcinoma,
miR-338 expression was significantly increased in both
blood and tissue samples. It might appear to be a potential
biomarker for early detection in colorectal carcinoma [23].
In gastric carcinoma, miR-338 was epigenetically silenced
and its reduction was related to pathological variables.
Overexpression of miR-338 could suppress cell prolifera-
tion, migration, invasion and tumorigenicity [24].
Moreover, combined with other six miRNAs, miR-338
could be used to predict gastric cancer prognosis [33].
Despite in cancer, miR-338 was also involved in idiopathic
pulmonary fibrosis [34].
This is the first study to identify the biological
function of miR-338-3p in liver fibrosis. Our results
demonstrated that miR-338 precursor transfection
suppressed the activation and proliferation of HSC-
T6, whereas inhibition of miR-338-3p promoted cell
activation and proliferation.
To understand the underlying mechanism of miR-338-
mediated inhibition of proliferation, we identified CDK4,
a member of the cyclin-dependent kinase family, as a
candidate target gene. CDK4 usually work with Cyclin D
to regulate the cell cycle in G1/S stage. Aberrant activa-
tion of CDK4 was closely associated with various kinds
of carcinomas. CDK4 expression is significantly upregu-
lated in lung cancer tissues and function as an important
element for cell proliferation [35, 36]. In breast cancer,
inhibition of CDK4 can induce G1 arrest [37]. These
observations suggest that inhibition of CDK4 might be
beneficial for cancer treatment. An increasing body of
clinical trials targeting CDK4 has been launched. How-
ever, the role of CDK4 in liver fibrosis remains largely
unknown. In this study, Luciferase reporter assay
showed that there was a combination of miR-338 and
CDK4. Hence, we deduced that miR-338-3p inhibited
HSCs’ activation and proliferation likely through silen-
cing CDK4. Our data indicated that restoring CDK4
expression could partially rescue miR-338-inhibited cell
activation and proliferation.
Conclusions
In conclusion, our study identified a new anti-fibrosis
miRNA that may play an important role in the develop-
ment of liver fibrosis.
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